Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeLLphi-308: Subcutaneous tarlatamab in extensive-stage small cell lung cancer
jRCT2061240070Phase 1Recruiting
- Sponsor
- Amgen
- Start
- Oct 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of tarlatamab in small cell lung cancer (SCLC) (3 arms), sponsored by Amgen. Primary endpoints: Dose-limiting toxicities (DLTs), Treatment-emergent adverse events (TEAEs) and 2 more. Started Oct 2024; status: recruiting.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2061240070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240070.